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Objective: The aim of the study was to determine whether Beta-hCG levels at various time 
intervals during the follow-up period after primary treatment of molar pregnancies could be 
used to predict progression of the disease later, in an attempt to shorten the period of 
surveillance. Furthermore an assessment of the demographic details and risk factors for the 
development of persistent trophoblastic disease was examined. Levels of compliance to the 
current surveillance protocol were evaluated. 
 
Method: A retrospective analysis of all patients diagnosed with molar pregnancies at 
Tygerberg Hospital, Cape Town from January 2000 to December 2010. 
 
Results: Among the 120 patients, 13 (19.7%) of complete moles and 10 (20%) of partial 
moles developed persistent trophoblastic disease. There was no statistical significance of the 
demographic data when comparing the two types of moles. 66% of complete and 50% of 
partial moles were lost to follow-up within the first six months of surveillance. A potential 
Beta-hCG cut-off value of 148mIU/ml at week 6 offered a sensitivity of 0.89 and specificity of 
0.88 that surveillance could be terminated. 
 
Conclusions: Patient compliance is a limiting factor in the evaluation of molar pregnancy 
surveillance. However, based on our results, the suggestion that termination of surveillance 
after primary evacuation could occur at 6 weeks if the Beta-hCG level was 148 mIU/ml or 
lower remains undecided, and it is our opinion that higher sensitivities and specificities are 
required. Further research is needed to solidify this claim. The acquisition of demographic 
information of our population remains a priority, in order for more informed decisions to be 
made. 




Doel: Die doel van die studie was om te bepaal of Beta-mCG vlakke of verskillende intervalle, 
gedurende die opvolg periode na primêre behandeling van mola swangerskappe gebruik kan 
word om siekte progressie te voorspel, en sodoende die tydperk van opvolg te verminder. 
Verder was die demografiese besonderhede en risiko faktore vir die ontwikkeling van 
persisterende trofoblastiese siekte ondersoek. Die nakoming tot die huidige toesighouding 
protokol was geevalueer. 
 
Metode:  ‘n Retrospektiewe analise van al die pasiënte wat gediagnoseer is met ‘n mola 
swangerskap by Tygerberg Hospitaal, Kaapstad vanaf Januarie 2000 tot Desember 2010. 
 
Resultate: Van die 120 pasiënte het 13 (19.7%) van die volledige molas en 10 (20%) van die 
gedeeltelike molas persisterende trofoblastiese siekte ontwikkel. Daar was geen statistiese 
belang in die demografiese data, wanneer die twee tipe molas met mekaar vergelyk is nie. 
66% van die volledige en 50% van die gedeeltelike molas was verlore met opvolg binne die 
eerste ses maande van opvolg. ‘n Potensiële Beta-mCG afsnywaarde van 148mIU/ml op ses 
weke het ‘n sensitiwiteit van 0.89 en spesifisiteit van 0.88 gewys dat toesighouding 
getermineer kan word. 
 
Opsomming: Pasiënt nakoming is ‘n beperkende faktor in die opvolg van mola 
swangerskappe. Alhoewel, gebaseer op ons resultate, ons kan voorstel dat terminasie van 
“surveillance/toesighouding” na primêre lediging, kan plaasvind op 6 weke indien die Beta-
mCG vlak 148mIU/ml of minder is, bly dit onbeslis. Dit is ons opinie dat hoër vlakke van 
sensitiwiteit en spesifisiteit nodig is. Verdere navorsing is nodig om hierdie voorstelling te 
staaf. Die invordering van demografiese inligting van ons populasie bly ‘n prioriteit, om 
sodoende  meer ingeligte besluite te neem. 
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Introduction and Literature Review 
Gestational trophoblastic disease (GTD) defines a heterogenous group of interrelated 
lesions arising from the epithelium of the placenta. Hydatidiform molar (HM) pregnancy is 
the most common form of GTD; this includes both partial hydatidiform molar (PHM) and 
complete hydatidiform molar (CHM) pregnancies [1]. The pathogenesis of GTD is unique 
because the maternal tumour arises from gestational rather than maternal tissue. All these 
conditions exhibit proliferation of both cytotrophoblast and syncytiotrophoblast cells. 
Complete (CHM) and partial moles (PHM) are non-invasive, localized tumours that develop 
as a result of an aberrant fertilization event that leads to a proliferative process.  
 
At the 2000 International Federation of Obstetrics and Gynecology (FIGO) meeting, the term 
‘gestational trophoblastic neoplasia’ (GTN) was recommended for patients whose serum 
beta-human chorionic gonadotrophin (Beta-hCG) level failed to regress in the absence of a 
normal pregnancy. These patients, similar to those with choriocarcinoma, need 
chemotherapeutic treatment. 
 
The incidence of GTD varies widely in different regions of the world [2]. The incidence of 
hydatidiform mole ranges from 23 to 1299 cases per 100,000 pregnancies, while GTN is less 
common. North American and European countries tend to report low or intermediate rates 
of disease, whereas Asian and Latin American nations often have high rates. The incidences, 
reported in literature, from Europe and North America are quoted as 0.5 to 1 per 1000 
pregnancies per year, whereas those reported from South East Asia, Indonesia, India and 
Turkey are as high as 2 to 12 per 1000 pregnancies per year.  
One reason for this variation is that epidemiologic data on GTD are limited by the rarity of 
the disease and inaccurate ascertainment of the number of cases as a function of the 
number of gestational events in the population, including normal pregnancies, ectopic 
pregnancies and miscarriages. Another reason for the differences in incidence worldwide is 
the discrepancy between population and hospital-based data. Due to the explanation 
mentioned above, the difficulty in estimating the true number of gestational events in a 
given population often necessitates the calculation of incidence based on the number of 
pregnancies recorded by a single institution. Very few countries worldwide have registries 
Stellenbosch University  http://scholar.sun.ac.za
 8 
whereby all molar pregnancies are recorded, this is especially true for under-developed 
countries. 
There is no accurately recorded data for the incidence of molar pregnancies in South Africa. 
One study reported the incidence of molar pregnancies in Kwazulu-Natal, South Africa to be 
1.16 per 1000 pregnancies. Whether this holds true for the Western Cape population and 
the rest of South Africa is not certain.  
 
The two main risk factors for GTD are extremes of maternal age (especially over age 35 
years) and a history of previous GTD [3]. The most well established risk factor for GTD is 
maternal age. Compared to the risk of GTD in the general population of reproductive-age 
women, the risk is significantly increased in those older than age 35, and slightly increased 
in those under age 20[4]. Nevertheless, most cases of GTD occur in women under age 35 
because of the greater number of pregnancies among younger women. It has been 
postulated that the ova of females of advanced age are more susceptible to abnormal 
fertilisations. 
 
The presence of a previous molar pregnancy increases the risk of a second molar pregnancy 
(complete or partial) to 1-2 %. The risk of a third molar pregnancy rises to 15-20 % [5]. 
Studies from the United States have found that women with a history of one molar 
pregnancy (partial, complete, or persistent GTN) have an approximately 1 % chance of 
recurrence in subsequent pregnancies (compared to a 0.1 % incidence in the general 
population of the United States). The recurrence rate is much higher after two molar 
pregnancies (16 to 28 %)[6]. 
 
Assisted reproductive technology has enhanced the fertility potential of older women, 
which may increase the proportion of cases in this age group. This is of concern because 
malignant sequelae occur more frequently in older patients [7]. 
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Other risk factors that have been associated with GTD include current smoking (>15 
cigarettes per day), maternal blood type AB, A, or B, history of infertility, nulliparity, and use 
of oral contraceptives (although oral contraceptives do not increase the risk of developing 
post-molar trophoblastic neoplasia [8])[9]. The mechanism for these associations has not been 
established and increased risk has not been demonstrated consistently.  
 
Hydatidiform molar pregnancies constitute approximately 80 % of all cases of GTD. Molar 
pregnancies comprise both CHM and PHM. These two entities have different 
histopathologic and chromosomal features, and more importantly their potential for 
persistence and progression to metastasis vary considerably too. Studies in the United 
Kingdom have reported malignant change in 15 % of CHM’s and 0.5-1 % of PHM’s [10, 11]. 
 
Genetics of molar pregnancy 
Complete mole genetics — A complete mole most commonly has a 46,XX karyotype, with 
all chromosomes of paternal origin [12]. This results from fertilization of an "empty" egg (ie, 
absent or inactivated maternal chromosomes) by a haploid sperm that then duplicates 
(46,YY moles do not occur because this karyotype is lethal). A small number (3 to 13 %) of 
complete moles have a 46,XY chromosome complement; this is thought to occur when an 
empty ovum is fertilized by two sperm  [12]. A few complete moles have a 46,XX karyotype 
but develop from fertilization of an empty ovum by two sperm. Because the nucleus is 
entirely paternal in origin, a complete mole is actually a paternal allograft in the mother. 
Aneuploidy can also occur. 
 
Rarely, complete moles are biparental and are associated with an autosomal recessive 
condition predisposing to molar pregnancy. These patients often have recurrent 
hydatidiform moles. This defect is likely due to dysregulation of genomic imprinting, in 
some cases related to a mutation at the 1.1 MB region on chromosome 19q13.4. As an 
example, women with biparental complete mole have significant underexpression of 
p57(KIP2), which is the product of CDKN1C (an imprinted, maternally expressed gene).  
Compared with women with androgenic complete moles, women with biparental complete 
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moles have a very high risk of recurrence, and also an increased risk of persistent 
trophoblastic disease. In one series of 152 pregnancies among 37 women with familial 
recurrent mole, complete mole and partial moles occurred in 74 and 4 % of pregnancies, 
respectively. A normal pregnancy developed in only 5 %, the remainders were described as 
spontaneous abortions (17 %) [13]. 
 
Partial mole genetics — Partial moles are pathologically and karyotypically distinct from 
complete moles. They are usually (about 90 %) triploid (69,XXX, 69,XXY, rarely 69,XYY) due 
to the fertilization of an ovum (one set of haploid maternal chromosomes) by two sperm 
(two sets of haploid paternal chromosomes). Flow cytometry studies have revealed a 
variety of other karyotypes in the remaining 10 %, although the true existence of 
nontriploid partial mole has been challenged [14]. The fetal or embryonic tissue that is 
present with a partial mole will most commonly have a triploid karyotype. 
 
Histology of molar pregnancy 
Hydatidiform moles are characterized by a marked proliferation of villous trophoblast 
associated with hydropic swelling of the chorionic villi. A major difference between the two 
types of molar pregnancy is that complete moles typically do not contain foetal/embryonic 
tissue and partial moles do, although foetal/embryonic tissue may be present in complete 
moles [15].  
The chorionic villi of a complete mole are diffusely hydropic and surrounded by 
hyperplastic, often atypical, trophoblast (table 1). Foetal tissue is not typically present. A 
twin pregnancy may be complicated by GTD, with a combination of a normal conceptus and 
a mole (complete or partial) and viable foetus or two moles. With the advent of 
ultrasonography at earlier gestational ages, molar pregnancies are being detected 
increasingly early, often as early as eight or nine weeks of gestation. The histologic features 
so characteristic of traditional complete moles, large hydropic villi and extensive 
trophoblast hyperplasia, are not typically seen at these early stages of development. 
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There are, however, distinctive histologic features seen in these "early complete moles" 
(often defined as a complete mole identified before 10 weeks gestational age). These 
include a cellular, myxoid-like villous stroma; markedly irregular villous contours (referred 
to as "toes and knuckles"); karyorrhectic debris visible in the villous stroma; and atypical 
trophoblasts (both villous and extravillous). Trophoblastic proliferation is not as marked as 
in more mature moles [16].  
 
In contrast to complete mole, a partial mole often contains normal appearing chorionic villi 
and fetal tissue admixed with hydropic villi (Table 1). The hydropic changes are focal and 
less prominent with less trophoblastic hyperplasia and atypia. Marked scalloping of 
chorionic villi and trophoblastic stromal inclusions are also seen. Differentiation of a partial 
mole from a hydropic abortus may be problematic. However, hydropic abortuses usually 
have a spectrum of villous sizes versus the two populations of villi in partial moles. Also, 
abortuses will have attenuated trophoblast over the surface of the hydropic villi while 
partial moles show at least modest trophoblastic proliferation [16]. 
 
Biochemistry of molar pregnancy 
Gestational trophoblastic diseases all share a common biochemical marker, human 
chorionic gonadotrophin (hCG). HCG is a glycopeptide hormone, produced by syncytial 
trophoblastic tissue. It consists of 2 subunits, polypeptide chains alpha and beta. The beta 
chain is unique to hCG, while the alpha chain is shared with LH, FSH and TSH. This hormone 
is used to detect normal and abnormal pregnancy states. HCG is easily measured 
quantitatively in both urine and blood, and hCG levels have been shown to correlate with 
the volume of trophoblastic tissue present. In normal pregnancy the hCG is intact and 
hyperglycosylated (hCG-H) during the first trimester of pregnancy. In an abnormal 
pregnancy or a cancer state of trophoblastic tissue, there exists many subtypes of Beta-hCG; 
namely free-Beta-hCG, Beta-core, nicked-free-Beta and c-terminal peptide. Due to this array 
of subtypes, it has become increasingly necessary to produce commercial assays that are 
able to detect all subtypes. These assays are expensive and not readily available worldwide 
and as such, the risk of false negative test results in cases of trophoblastic disease is 
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unfortunately high. False positive readings are also possible due to cross-reacting 
antibodies, but these antibodies do not cross into the urine and thus false positive results 
can be excluded by the use of a urine test for confirmation. Molar pregnancies usually 
present with HCG values that are markedly elevated, approximately 40% of patients have 
HCG exceeding 100 000 mIU/ml. The serum hCG concentration is always elevated in women 
with GTD and is usually higher than that observed with intrauterine or ectopic pregnancies 
of the same gestational age [17]. 
 
The Beta-hCG molecules, abundantly produced with molar pregnancies, exhibit specificity 
for the TSH receptors and have the potential to cause thyrotoxicosis. A serum Beta-hCG of 
50,000 mIU/ml is approximately equivalent to a TSH level of 35 IU/ml.  
The reference range for TSH at our laboratory is 0.35 to 4.5 IU/ml. Levels below 0.35 IU/ml 
signify a significant increase in the potential for thyrotoxicosis and thyrotoxic storm. These 
complications arise as a result of the large amount of circulating HCG in the maternal blood. 
Diminished levels of TSH associated with elevated T4 will support the diagnosis of 
thyrotoxicosis. Free T4 (unbound, active thyroid hormone) must be checked in all patients, 
as elevated thyroid-binding globulin, as seen in pregnancy, and variable levels of albumin 
will alter free T4 levels and thus change measures of bioactive hormone.  
Frequently patients exhibit clinical signs of thyrotoxicosis including hyperthermia, 
supraventricular tachycardia (SVT), congestive heart failure, gastrointestinal (GI) symptoms, 
and confusion without the complete picture seen with Graves’ disease [18]. 
 
Gestational trophoblastic neoplasia 
Factors that have consistently been shown to be predictors of development of GTN after a 
complete mole are:  
1. Beta-hCG level over 100,000 mIU/ml 
2. Presence of large (>6 cm in diameter) theca lutein cysts 
3. Significant uterine enlargement 
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These are all signs of marked trophoblastic proliferation [19]. Complete moles with factors 
associated with increased risk of persistent disease are considered high-risk complete 
moles. For partial moles, no clinical factors have been identified that are associated with 
increased risk of GTN. 
 
Surveillance 
After the primary management of a suspected or histologically-confirmed molar pregnancy 
the surveillance period begins. This period involves the evaluation of serial Beta-hCG levels. 
This is done in order to detect the presence of persistence, recurrence or malignant 
transformation early so that the method of secondary treatment can be offered early and 
improve the chances of success.  
The International Federation of Gynecologists and Obstetricians (FIGO) standardized Beta-
hCG criteria for the diagnosis of post-molar gestational trophoblastic disease. Any of the 
following findings during the period of gonadotropin follow-up is suggestive of persistent 
GTD and warrants treatment [20]: 
• A plateau in the serum Beta-hCG concentration for at least four values over three 
weeks. 
• A serum Beta-hCG concentration that rises (by 10 % or greater) for three values or 
more over at least two consecutive weeks. 
• Persistence of detectable serum Beta-hCG for more than six months after molar 
evacuation. 
• Histologic confirmation of choriocarcinoma. 
 
Prophylactic chemotherapy after molar evacuation is widely practiced in developing 
countries in which poor medical and social resources limit effective follow-up [19]. However, 
this practice, which may cause later chemoresistance, is controversial and lacks universal 
acceptance. This practice is not offered at Tygerberg hospital.   
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The reasons for the need for a surveillance protocol are as follows: 
1. As previously mentioned these conditions carry the potential to develop persistence, 
recurrence or malignant transformation 
2. Early diagnosis allows for early secondary intervention (chemotherapy) which has an 
almost 100 % cure rate 
3. The prognosis worsens once detection of persistence is based on clinical rather than 
biochemical means. 
 
Previously, the follow-up of molar pregnancies, with Beta-hCG levels was continued to a 
total time period of two years. The method by which this was done was as follows; weekly 
levels were examined until levels reached undetectable levels, thereafter levels were 
evaluated monthly for six months, then 3-monthly for six months, and finally six-monthly 
twice. Currently this approach has been reserved for those patients with GTN.  
Traditional surveillance for post-evacuation development of persistence was as follows 
[21,22]: 
• Weekly Beta-hCG after evacuation until levels were below 5mIU/ml for 3 
consecutive weeks 
• Thereafter, monthly Beta-hCG tests for six months. 
• Serum Beta-hCG is also suggested in patients with a previous molar pregnancy six 
weeks after a subsequent normal pregnancy. 
 
This method of surveillance has numerous shortcomings. Petersen et al evaluated the 
impact on psychological symptoms, sexual function and quality of life. Feelings of 
depression and sadness have been attributed by patients to the diagnosis and failed 
pregnancy attempt to the involuntary delay in child-bearing as well as the need for constant 
surveillance. Grief was attributed to the loss of a potential child and feelings of uncertainty 
and confusion about their future reproductive potential. Fear of recurrence was also 
reported before and during subsequent pregnancies [23]. 
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Another major concern with the traditional surveillance method is the cost impact on both 
patients and the institutions that provide the care. At Tygerberg, patients are required to 
pay a fee for each visit to the clinic where surveillance is undertaken. This is due to the fact 
that this surveillance is considered a tertiary service provided by the state and thus a fee is 
payable by the patient. Bearing in mind that the majority of these patients are from a socio-
economically disadvantaged part of the population and that surveillance is only done at 
secondary and tertiary clinics, transport to these clinics is a financial burden for these 
patients. These factors have an effect on the compliance of these patients to the 
surveillance schedule which potentially has detrimental effects on their health. 
 
Numerous recent studies have addressed the issue of this protracted period of surveillance 
following molar pregnancies. Wolfberg et al, displayed a progression to persistent GTN in 15 
% of reported cases of CHM, and the rate of persistent GTN in those whose HCG levels fell 
spontaneously after evacuation, to undetectable levels was 0.2% [24]. This study 
recommended further investigation of this phenomenon in other reputable centres for 
validation of their findings with the intention of lowering the time period of follow-up for 
patients, especially those wishing to conceive. A follow up study by the same authors, 
showed that the risk of developing persistence after evacuation of CHM was 9 %, when 
Beta-hCG levels were below 200 mIU/ml in the fourth week or below 100 mIU/ml in the 
sixth week. Those patients with a Beta-hCG that declined to below 50 mIU/ml during their 
surveillance period were found to be at no more than 1.1% risk of developing persistent 
GTN. While levels above 2000 mIU/ml in the fourth week were associated with a 63.8 % risk 
of developing persistent GTN [25]. Another study from the Netherlands regarding CHM’s, 
showed that 13.3 % of patients required chemotherapy for persistent disease and none of 
those patients whose hCG levels spontaneously fell to normal after evacuation developed 
persistent molar disease. It was concluded that for those patients whose levels fell to 
normal within 2 months of evacuation, surveillance could be discontinued [26]. 
 
Lavie et al, attempted to determine the optimal duration of Beta-hCG surveillance after 
evacuation of PHM. The results supported the suggestion that a single undetectable Beta-
hCG level after evacuation was sufficient follow up to ensure remission in patients with 
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partial moles. However, poor compliance (34 % of patients were lost to follow-up during the 
post-evacuation surveillance period) of patients proved problematic [27]. Wolfberg et al 
evaluated 284 women with PHM that completed their surveillance period and found that 
none of those that had spontaneous decline (238 patients) in serum Beta-hCG levels to 
undetectable levels developed subsequent persistent GTN [28]. 
Wiesma et al, retrospectively analysed Beta-hCG levels in order to determine the risk of 
persistent GTN following PHM, and also aimed to review the present surveillance protocol 
being used. This study indicated that 1.7 % of all PHM patients needed treatment for 
malignant sequelae. In contrast, no patient diagnosed with PHM had a biochemical or 
clinical relapse after achieving undetectable levels of Beta-hCG, consistent with previous 
studies. The authors concluded that patients who have had a PHM could be followed by 
Beta-hCG weekly assays until normal levels are achieved and then follow-up could be safely 
discontinued [29].  
 
In 2007, a regional trophoblastic unit in the United Kingdom revised their surveillance 
protocol based on the evaluation of molar pregnancies in their database over a ten-year 
period. Previously, serum Beta-hCG measurements were taken every two weeks until the 
levels returned to normal. Thereafter, the surveillance period was based on the time taken 
for that level to be reached, before or after 56 days post-evacuation. Those patients that 
previously had levels return to normal after 56 days, were evaluated monthly for one year 
and then 3 monthly for a further year. In the study, 6 % of patients developed persistent 
disease and 98 % of these occurred within 6 months of evacuation. Thus the period of 
monitoring for uncomplicated cases, whose values returned to normal after 56 days, was 
decreased to six months [30]. 
 
Kerkmeijer et al [31] reviewed all hydatidiform molar pregnancies in The Netherlands from 
1995 to 2004. Of all those patients that spontaneously normalised after evacuation, only 
one developed recurrent disease. The majority of these patients were followed up for 
approximately 6 months. 
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Aim of the Study 
The primary objective of the study is to determine whether Beta-hCG levels at various time 
intervals during the surveillance period after primary treatment of molar pregnancies can be 
used to predict progression of the disease later. This is an attempt to shorten the period of 
surveillance. 
 
The secondary objectives of the study are to evaluate the demographic details of patients 
affected by molar pregnancies in the Tygerberg Academic Hospital (TBH) drainage area of 
the Western Cape (Table 2). 
 
An attempt to shorten the surveillance period before remission (the presence of three 
consecutive undetectable Beta-hCG levels) has been confirmed has not been undertaken 
previously. This approach is intended to take into account the high prevalence of non-




This is a retrospective descriptive study. Data was collected of all cases of CHM’s and PHM’s 
treated and followed up by the Unit of Gynaecologic Oncology at Tygerberg Hospital 
between January 2000 and December 2010. 
 
All molar pregnancies diagnosed at Tygerberg Hospital, or those diagnosed elsewhere but 
that received treatment at Tygerberg Hospital were used in this study. The cases were 
drawn from the unit of gynaecologic oncology and the department of anatomical pathology. 
All files were collected from the medical records department and all data was recorded onto 
anonymous data sheets. The data was entered manually onto the data acquisition form and 
then transferred onto an Excel spreadsheet and analysed by a statistician from the 
Department of Biostatistics from the University of Stellenbosch statistician.  
 
Stellenbosch University  http://scholar.sun.ac.za
 18 
Sample Size Calculation 
The sample size was calculated to offer as much precision as possible in the calculation of 
the primary objective. For the purposes of this study the objective was to determine 
whether a Beta-hCG of < 5 at 2 months after evacuation was sufficient to assume that 
persistent disease would not occur.  Thus, for all patients the Beta-hCG at 2 months after 
evacuation (or the closest possible value) was recorded.  In addition, based on follow-up 
data available, it was possible to determine whether progression or malignancy for any 
patient did actually occur.  Using this information, the sensitivity and specificity of the 
proposed cut-off of <5 could be evaluated, as well the positive predictive value and negative 
predictive value.  Thus, the sample size was determined to offer the best possible precision 
in the estimation of the sensitivity and specificity in particular. 
Based on past literature it was expected that approximately 15 % to 20 % of CHM’s would 
ultimately result in progression or malignancy.  Therefore, a sample size of 150 molar 
pregnancies would offer an estimated 15% precision in the estimation of the sensitivity, 
given the relatively small population of molar pregnancies.   
 
Analysis of Data 
MS Excel was used to capture the data and STATISTICA version 9 (StatSoft Inc. (2009) 




As mentioned previously, the primary objective was to determine whether the Beta-hCG 
levels at 6 weeks, 2 months, 3 months or 4 months after primary treatment could be used to 
predict persistence or malignancy.  The sensitivity and specificity of the proposed cut-off of 
a Beta-hCG of <5 was evaluated, as well as the positive and negative predictive value.  
Therefore, the primary objective was that of sensitivity and specificity.  If the proposed cut-
off value at 2 months after evacuation was found to be both highly sensitive and highly 
specific then this could serve as motivation for a reduction of the follow-up period beyond 2 
months after evacuation. 
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Analysis of Other Objectives: 
Other authors have suggested various different cut-off values for prediction of molar 
pregnancies.  These vary according to the cut-off value itself as well as the recommended 
time period at which to make the prediction.  The former analysis involves the construction 
of a receiver-operating curve (ROC) to determine the best cut-off value that will result in the 
highest possible combination of sensitivity and specificity.  The ROC analyses were repeated 




Summary statistics were used to describe the variables.  Distributions of variables were 
presented with histograms and frequency tables. Means were used as the measures of 
central location for ordinal and continuous responses and standard deviations as indicators 
of spread. 
 
For any other analyses, the following general analysis rules applied: 
Relationships between two continuous variables were analysed with regression analysis and 
the strength of the relationship measured with the Pearson correlation, or Spearman 
correlation, if the continuous variables were normally distributed. If one continuous 
response variable was to be related to several other continuous input variables, multiple 
regression analysis were used and the strength of the relationship measured with multiple 
correlation. 
 
The relationships between continuous response variables and nominal input variables were 
analysed using appropriate analysis of variance (ANOVA). When ordinal response variables 
were compared versus a nominal input variable, non-parametric ANOVA methods will be 
used. For completely randomized designs the Mann-Whitney test was used.  
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The relation between two nominal variables was investigated with contingency tables and 
likelihood ratio chi-square tests. 
 
A P-value of p < 0.05 represented statistical significance in hypothesis testing and 95 % 
confidence intervals (CI) were used to describe the estimation of unknown parameters. 
 
The study was approved by the local ethics committee. (Ethics number N11/02/030) 
 
Results:  
One hundred and twenty patients with molar pregnancies were managed at Tygerberg 
Hospital between January 2000 and December 2010.These patients were: 
• primarily diagnosed with a molar pregnancy and treated at Tygerberg Hospital, or 
• diagnosed with a complicated molar pregnancy at a peripheral district hospital and 
transferred to Tygerberg Hospital for primary management, or 
• managed at a peripheral hospital and during the surveillance period, found to have 
persistent disease requiring chemotherapy. 
 
Demographic data 
Patient ages ranged from 13 to 51 years with a mean maternal age of 26.5 years (95% CI 
24.9 to 28.2). The mean age for the PHM group was 26.4 years (95% CI 24.1 to 28.8) and 
26.0 years (95% CI 23.7 to 28.4) for the CM group as represented by figure 2. There was no 
significant difference between the two groups, with a P-value of 0.633 (table 3). 
 Twenty-five patients were 35 years or older, and of these 8 (32%) developed persistent 
GTD. Ninety-five patients were younger than 35 years, and only 16 (16.8%) developed 
persistent GTD. There was no statistical significance between these two groups for the 
development of persistence, with a P-value of 0.057 (table 4).  
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The histological diagnosis was that of CHM in 66 cases (55%), PHM in 50 cases (42%) and 
unknown in 4 cases (3%), as no histological specimens were evaluated for the latter group. 
 
The mean parity in this study population was 1.1 (95% CI 0.8 to 1.4). The mean parity for the 
PHM group was 1.2 (95% CI 0.8 to 1.7) and 0.9 (95% CI 0.5 to 1.4) for the CM group as 
represented by figure 3. There was no significant difference between the two groups, with a 
P-value of 0.099 (table 3).  
The mean gravidity in this study population was 2.2 (95% CI 1.9 to 2.5). The mean gravidity 
for the PHM group was 2.4 (95% CI 1.9 to 2.9) and 2.1 (95% CI 1.6 to 2.5) for the CHM group 
as represented by figure 4. There was no significant difference between the two groups, 
with a P-value of 0.094 (table 3). The number of primigravid females with CHM’s and PHM’s 
was 35 (58.3%) and 20 (40%) respectively. 
 
The mean age of menarche in this study population was 13.71 (95% CI 13.47 to 13.98). The 
mean age at menarche for the PHM group was 13.84 (95% CI 13.41 to 14.27) and 13.62 
(95% CI 13.30 to 13.94) for the CHM group as represented by figure 5. There was no 
significant difference between the two groups, with a P-value of 0.404 (table 3).  
 
The mean age of the patients at their first pregnancy was 20.46 years (95% CI 19.7 to 21.21). 
The mean age at first pregnancy for the PHM group was 19.86 years (95% CI 18.97 to 20.75) 
and 20.58 years (95% CI 19.47 to 21.68) for the CHM group as represented by figure 6. 
There was no significant difference between the two groups, with a P-value of 0.445 (table 
3). 
 
Only 67 of the 120 patients had a serum TSH level evaluated on admission. The mean TSH 
value in this subgroup was 2.6 (95% CI -0.8 to 5.9). The mean TSH level for the PHM group 
(24 samples) was 0.8 (95% CI 0.2 to 1.3) and for the CHM group (43 samples) was 3.6 (95% 
CI -1.6 to 8.9) (figure 7). There was no significant difference between the two groups, with a 
P-value of 0.116 (table 3). 
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The mean initial Beta-hCG for the study population was 534415.5 (95% CI 368889.6 to 
699941.3). The mean initial Beta-hCG for the PHM group was 625496.2 (95% CI 344874.4 to 
906118.0) and for the CHM group 472715.6 (95% CI 265063 to 680367.7) (figure 8). There 
was no significant difference between the two groups, with a P-value of 0.855 (table 3). 
 
Sixty two percent of patients with PHM’s and 53% of the patients with CHM reported the 
use of nicotine (figure 9). 
 
The most common method of primary treatment for molar pregnancies at Tygerberg 
Hospital was an evacuation of the uterus, either by suction curettage or sharp curettage. 
98% of the patients were treated using a curettage technique. Other treatment modalities 
used were Total Abdominal Hysterectomy (TAH) and Salpingectomy (Figure 10). The 
salpingectomy was performed on a patient diagnosed with an ectopic pregnancy upon 
which a histological diagnosis of a CHM was made. 
 
Evaluation of Beta-hCG Surveillance 
Persistence of gestational trophoblastic disease was diagnosed on the basis of Beta-hCG 
levels gathered after primary treatment was performed. The diagnosis of persistence was 
made on the basis of the guidelines as set out by the International Federation of 
Gynaecologists and Obstetricians (FIGO) and described in the introduction. 
 
Fifty-three of the 66 patients (80.3%) with CHM spontaneously developed undetectable 
Beta-hCG levels during surveillance after primary treatment. Forty of the 50 patients (80%) 
with PHM spontaneously developed undetectable Beta-hCG levels during surveillance after 
primary treatment. Thus, 19.7% (n=13) of patients with CHM and 20% (n=10) of patients 
with PHM developed persistence. 
The age, parity, gravidity and initial Beta-hCG values of patients with persistent GTD did not 
differ significantly from those who did not develop persistent GTD. (Table 5). 
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The outcomes of the patients that presented for surveillance for the presence of persistent 
disease is shown in table 6. 
Eighty percent of both CHM’s and PHM’s required no chemotherapy and went into 
spontaneous remission, while approximately 20% developed persistence during the 
surveillance period. All of the cases of persistence were diagnosed within the first 9 months 
of follow-up and appropriate measures were taken. 
Sixty-six percent of CHM’s and 50 percent of PHM’s were lost to follow-up in the first 6 
months after primary treatment. 
Of the total number of molar pregnancies evaluated during this study, 74 % (CHM) and 60 % 
(PHM) did not follow up and never reached undetectable levels of Beta-hCG. 
Eighty-six % (CHM) and 94 % (PHM) of molar pregnancies missed at least one visit during the 
first 6 months after primary treatment was performed. 
 
Four Receiver Operator Characteristic (ROC) curves were created to compare Beta-hCG 
levels of partial and CHM’s in an attempt to ascertain potential cut-off values at certain time 
intervals during the surveillance period at which follow-up could be safely terminated (table 
7). 
The intervals at which this potential cut-off value was evaluated were week 4, week 6, 
month 2 and month 3. Although numerous ROC curves were calculated, those mentioned 
above were determined to be the most suitable time intervals for evaluation based on 
current knowledge of GTD remission. 
 
At Week 4, 83 cases were evaluated at this time interval. A Beta-hCG of 148 conveyed the 
best sensitivity and specificity to be considered a potential cut-off of surveillance (figure 11 
and table 8). 
 
At Week 6, 85 cases were evaluated at this time interval. A Beta-hCG of 148 conveyed the 
best sensitivity and specificity to be considered a potential cut-off of surveillance (figure 12 
and table 8). 
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At Month 2, 86 cases were evaluated at this time interval. A Beta-hCG of 43 conveyed the 
best sensitivity and specificity to be considered a potential cut-off of surveillance (figure 13 
and table 8). 
 
At Month 3, 76 cases were evaluated at this time interval. A Beta-hCG of 11 conveyed the 
best sensitivity and specificity to be considered a potential cut-off of surveillance (figure 14 
and table 8). 
 
Discussion 
Tygerberg Hospital is a combined secondary and tertiary medical facility that serves a large 
portion of the Western Cape Province, comprising both urban and rural regions. Numerous 
molar pregnancies are thus managed by the other secondary level hospitals in the clinic and 
never present to Tygerberg if spontaneous remission after primary evacuation occurs. 
In the index study the true incidence of molar pregnancies could not be established because 
the total number of conception events (denominator) and the total number of molar 
pregnancies (numerator) in the Tygerberg Hospital drainage area could not be ascertained  
In the index study the calculation of the incidence of persistence was also not possible 
because the number of molar pregnancies in the entire Tygerberg drainage area could not 
be determined. 
 
It is not feasible to send specimens for histological analysis of all miscarriages that occur in 
the region, thus a high index of suspicion based on ultrasound findings is an important 
screening tool which assists in the decision for further testing, either Beta-hCG or 




Increasing age is the best-established risk factor for CHM with women over 40 years of age 
having a 5 to 10-fold higher risk than younger women [32]. Because of the higher number of 
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pregnancies in younger women, however, most complete moles occur in women under 35. 
However, maternal age has not been associated with risk of PHM. Numerous authors have 
shown an association between older maternal age and an increased risk of persistent 
disease [3,4]. 
The index study did not show a significant difference in the ages of those that developed 
CHM or PHM. As expected, more molar pregnancies were diagnosed before the age of 35 
years, in line with previous studies. 
The odds ratio for having a molar pregnancy after the age of 35 years in the index study is 
2.35. This is considerably lower than that reported by another author, namely 5.2, where 
age > 40 years was evaluated [33]. 
 
The index study showed that women over the age of 35 years were somewhat more likely to 
develop persistent disease, although this did not reach statistical significance (P = 0.057). 
 
Parity and gravidity 
There has been reported that nulliparous or females of low parity have an increased risk of 
developing molar pregnancies [33]. In the index study, primigravidae made up 58.3% and 40% 
of complete and PHM groups respectively. This is merely a descriptive analysis that 
correlates to previous findings. 
 
Initial Beta-hCG 
Furthermore, the index study was unable to corroborate previous reports of the importance 
of serum Beta-hCG at presentation, due to the statistical insignificance of the index study 
data [25]. Ayhan et al determined that pre-evacuation Beta-hCG levels above 100,000 
mIU/mL have been found to predict persistent disease, but never with sufficient precision to 
guide management [34]. Niemann et al found that all their patients diagnosed with CHM’s 
that presented with initial Beta-hCG levels less than 49 000 mIU/ml had spontaneous 
remission [35]. This level is extremely low and offers no assistance to the majority of patients, 
usually presenting with values in excess of 100 000 mIU/ml. The Beta-hCG levels at 
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presentation, in the index study, showed no statistical significance in predicting the 
development of persistence for either benign forms of molar pregnancy. 
 
Menarche 
Other authors have reported that the risk of developing gestational trophoblastic neoplasia 
may also be linked to certain hormonal factors. This is based on the increased risk noticed in 
women with menarche after the age of 12, and the previous use of oral contraceptives. Our 
data did not support the association between menarche after age 12 and the increased risk 
of persistent disease [36]. 
 
TSH (Thyroid Stimulating Hormone) 
In the index study, 24 cases of PHM had TSH levels recorded, of which 12 were less than 
0.35 IU/ml (50%), while 43 cases of CHM had TSH levels recorded, of which 16 were less 
than 0.35 IU/ml (37%). Although these tests were requested, there is not much evidence to 
suggest that these values alerted the clinicians to any potential threat, and no notes were 
made on positive symptoms of thyroid crisis, thyrotoxicosis or thyroid storm. 
The presence of hyperthyroidism is a marker for increased risk for the development of 
trophoblastic gestational neoplasia. Due to the absence in the reporting of thyroid 
symptoms it was not possible to determine the significance of the decreased TSH levels in 
the index study and was thus not evaluated further. 
 
Evaluation of the Beta-hCG surveillance period   
Persistence 
The risk of persistent trophoblastic disease differs between PHM’s and CHM’s. The 
incidence of persistent disease in the index study was found to be 19.7% for CHM’s and 20% 
for PHM’s (table 7). These values are much higher than the reported incidences in other 
studies, 15% for CHM’s and 0.5% for PHM’s [28,44,45]. The reasons for this difference in the 
incidences is largely based on the biased nature of patients referred to Tygerberg Hospital 
and have already been mentioned.  
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Wolfberg et al concluded that the risk of persistent trophoblastic neoplasia after Beta-hCG 
values have fallen to less than 5 mIU/mL was very small and may even approach zero [28]. 
Another study by Wolfberg et al concluded that women with PHM with serum Beta-hCG 
levels that spontaneously declined to undetectable levels after evacuation were at 
exceedingly low risk of developing persistence [37].  
Feltmate et al and Batorfi et al re-evaluated the length of the follow-up period after molar 
pregnancies. None of the 150 patients in Batorfi’s study and none of the 400 patients in 
Feltmate’s report who achieved at least one undetectable serum HCG level had any 
evidence of persistent trophoblastic disease [38,39].  
In the index study, 65 patients had at least one Beta-hCG level less than 5 mIU/ml during the 
first 6 months after evacuation, and only 3 (4.6%) of those developed persistent disease. 
This is in keeping with previously reported data. 
 
Remission 
Remission is diagnosed when a patient achieves three consecutive undetectable Beta-hCG 
levels during the surveillance period.  
In the index study, 23 patients from each group went into remission. Three (13%) patients 
from the CHM group and 1 (4.3%) from the PHM group went into spontaneous remission 
after 6 months of surveillance (table 9). The majority of both groups went into remission 
before 6 months had elapsed after their primary treatment. These patients required no 
chemotherapy at any stage during their surveillance period, proving the validity of the 
current molar surveillance protocol.  
Kerkmeijer et al reported that among 265 patients with spontaneous normalization, only 1 
developed persistent disease [31].  
 
Patients who became pregnant during the 6-month follow-up interval (n=6) were 
considered to be in remission if they had evidence of a normal pregnancy. No postpartum 
Beta-hCG evaluation was performed after the subsequent pregnancy as recommended by 
the FIGO oncology committee [20].  
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Currently, uncomplicated molar pregnancies that enter remission in less than 6 months of 
surveillance are not required to follow up any further. The data from the index study 
supports this finding.  
 
Compliance 
The surveillance period refers to the time period after the primary evacuation when Beta-
hCG levels are evaluated (table 7). 
The method of surveillance of molar pregnancies after primary evacuation of the uterus is 
standardized according to the recommendations by the FIGO Oncology Committee [20] as 
described in the introduction.  
In the index study, the Beta-hCG level used to determine the presence of remission was a 
value of less than 5 mIU/ml. This value is internationally accepted as the upper level of an 
undetectable reading, despite the current assay used being more capable of detecting lower 
levels. 
 
The method of surveillance at Tygerberg Hospital is the same for all types of molar 
pregnancies.  Once persistence is diagnosed, patients are managed according to the 
International Federation of Gynecology and Obstetrics (2000) scoring system for gestational 
trophoblastic neoplasia, by prognostic factors (table 9). Those that obtain a score of 0 to 6 
(low risk) are eligible for monotherapy and those 7 or greater (high risk) show a high risk for 
resistance to monotherapy. 
 
After primary treatment and discharge from the hospital, patients are given a follow-up 
date in one week at the Gynaecology Oncology unit where the Beta-hCG surveillance is 
commenced. These results are recorded and evaluated by a senior nurse. If the value is on 
the decline, the patient is given another follow-up date for the next week. This continues 
until 3 consecutive undetectable levels are reached. If the level is reaching a plateau or 
rising, the patient is presented to the gynaecologic oncologist for evaluation. 
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The generally used protocol worldwide for Beta-hCG surveillance, which is followed by 
Tygerberg Hospital is the following:  
In cases of CHM’s, it is recommended to check serum Beta-hCG levels weekly until 
undetectable for three consecutive weeks then monthly until undetectable for six 
consecutive months.  
For patients with PHM’s the monthly Beta-hCG checking is recommended only until 
undetectable for three consecutive months if serum Beta-hCG becomes negative within 7 
weeks after curettage. Otherwise the same protocol is used as for patients with CHM’s [34]. 
 
Numerous studies found patient compliance to the protracted period of Beta-hCG 
surveillance to be poor.  Only 16% of patients completed the entire period of Beta-hCG 
monitoring in the study from the Netherlands [23]. Other authors reported non-compliance 
in 49.5% and 40% of their patients due to either failure of follow up before undetectable 
levels were reached or missing data in their respective study populations [29,39]. Compliance 
in this study was also very poor with only 36% complying with the surveillance protocol. 
 
Numerous patients failed to follow up for further Beta-hCG testing during the surveillance 
period and had to be contacted telephonically to ascertain whether any complications had 
developed. This contact was performed much later, sometimes a few years later, when the 
data was evaluated for this study in an attempt to improve the quality of the data. 
Patients were telephonically asked the following questions in an attempt to establish 
remission: 
1. Were there any episodes of abnormal vaginal bleeding during the subsequent 
months? 
2. Was admission to another institution required for gynaecological reasons? 
3. Had the patient fallen pregnant during the surveillance period? 
4. Had further evacuations been required? 
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5. Was any further or other treatment for the molar pregnancy provided by any other 
healthcare facilities? 
If all these questions were answered in the negative, it was accepted that the patient had 
entered remission and that no persistence had occurred. Although this was not the ideal 
method for determining persistence, it was the only plausible option available in order to 
collect information on molar pregnancies treated in the sample group. 
 
Evaluation of potential Beta-hCG cut-off values 
The cut-off values at specific time intervals were attained with the use of Receiver-Operator 
Characteristic (ROC) curves. If the diagnostic test is a continuous variable, as in the case of a 
measurement of Beta-hCG concentration in blood, then a ROC curve permits selection of a 
diagnostic threshold that can be used to predict adverse outcomes. By calculating the area 
under the ROC curve and comparing it with the area under the non-diagnostic line (the 
diagonal line running from the bottom left to the top right) one can determine if the test is 
better at predicting the outcome than chance alone. 
 
The time periods used were week 4, week 6, month 2 and month 3. The choice for the use 
of these intervals was based on the premise that a dramatic shortening of the surveillance 
period could be attained should these values prove significant. 
 
There were certain constraints to the evaluation of these time intervals, primarily due to the 
lack of compliance by the patients to their follow up visits. A large majority of the patients 
missed at least one visit during the first 6 months of follow up, but managed to attend the 
clinic later. With this in mind, the decision was made to impute no more than one data point 
within these four data points. For example, if a patient managed to attend on week 4 and 
month 2 and month 3, then the value of the Beta-hCG at week 4 was imputed into the data 
point for week 6. The value of the data imputed was always the same as the value 
immediately prior to the missed data point, so that an effective over-estimation of that 
point was made and in so doing, erring on the side of caution. If more patients had been 
Stellenbosch University  http://scholar.sun.ac.za
 31 
available for study and more data available, the cut-off points would have been much more 
accurate, offering higher sensitivities and specificities at each interval. 
 
The data point with the best predictive value for evaluation of a potential cut-off was that of 
Week 6. The highest numbers of patients were evaluated at this interval (N=85). The 
sensitivity and specificity of this cut-off value was 0.89 and 0.88 respectively. The area under 
the curve was 0.9, and the recommended cut-off value was a Beta-hCG of 148 mIU/ml. The 
sensitivity of this cut-off point implies that 89% of our patients that developed persistence 
were detected by the presence of a Beta-hCG value greater than 148 mIU/ml, implying that 
11% of the patients who developed persistence would not have been picked up had the 
surveillance period been terminated. However, 88% of patients that would not develop 
persistent disease would be correctly identified by a Beta-hCG value of less than 148 
mIU/ml. This evaluation suggests that 12% of patients with a Beta-hCG value of less than 
148 mIU/ml could develop persistent disease. Larger studies are needed to determine more 
accurate cut-offs that would hopefully have more clinically acceptable sensitivity and 
specificity levels. 
 
It is important to note that a shortened surveillance could enable women to attempt a 
subsequent pregnancy sooner and for socio-economic reason limit the visits for Beta-hCG 
testing, but could result in late development of neoplasia with increased morbidity and 
mortality. Data reported at the 2009 International Society for the Study of Trophoblastic 
Diseases (ISSTD) world congress of 22000 women with complete and partial hydatidiform 
moles in the UK suggest that either form can occasionally develop post-mole neoplasia after 
the Beta-hCG has returned to normal; however, the risk of missed gestational trophoblastic 
neoplasia can be reduced from one in 800 women to one in 1400 by following present UK 
guidelines as mentioned above [30]. 
 
Recommendations 
There are major pitfalls in the management of molar pregnancies in developing countries, 
with the majority of the effort being placed on the role of tertiary institutions, and a smaller 
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role on those smaller rural/district hospitals. However, the majority of the population does 
not have access to these larger facilities and rely solely on their local clinics for management 
and surveillance of this condition that has the potential for severe maternal morbidity and 
mortality. This emphasises the need for nurse training programs for detection of suspicious 
Beta-hCG results and appropriate referral. 
 
Failure in accurate diagnosis of molar pregnancies, particularly PHM’s (which are known to 
occur simultaneously with a normal pregnancy), remains a global problem. The costs 
involved in requesting histological confirmation of all adverse first trimester events is not 
affordable or feasible even in the most wealthy of countries. A possible solution to this 
dilemma could be the measurement of maternal Beta-hCG three to four weeks after a 
miscarriage has been diagnosed and treated, and if this result has not fallen as expected, 
the assumption of a molar pregnancy could be made and appropriate surveillance 
instituted. This method of surveillance could be tailored to that group of patients that fall 
into an ambiguous category and could be less stringent. This method of management would 
also require an initial measurement of Beta-hCG at presentation, which is not routinely 
performed. The management of ectopic pregnancies remains unchanged, but a more 
rigorous attempt at confirming a normal tubal pregnancy with histology should be 
emphasized. 
 
A reasonable recommendation to improve the way molars are managed would be to 
institute a national registry where all molar pregnancies could be documented for further 
epidemiological analysis and evaluation of treatment practices. The institution of such a 
registry could be made simpler by forming sub-registries affiliated with each tertiary 
institution that would be responsible for their own drainage area. This is a very important 
step in the improvement of our management of molar pregnancies and would be the first 
step in achieving better standards of care. The United Kingdom instituted their own molar 
registry in 1973 as an example, and has instituted changes to their surveillance protocol 
based on over 30 years of patient data. 
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Regional guidelines with regards to the surveillance period are already in place, but this 
study has demonstrated the inconsistency in the record keeping for this period and will 
hopefully be the driving force behind instituting changes in order to better manage these 
conditions, particularly the benign forms of the disease.  
Some highlighted recommendations follow: 
o The institution of a standardised data sheet (‘molar passport’) for these patients, in 
triplicate or duplicate (one to be kept in the patients’ file, one for a registry file in the 
gynaecology clinic and possibly a third card for the patient to keep as documentation 
should they follow up at other clinics) would aid in the evaluation of potential 
recurrence or persistence. Digitilisation of patient data would be ideal. 
 
o Sufficient contact details should be made available to those monitoring the patients 
for follow up and the patients that miss an appointment should be contacted so as 
to improve compliance and evaluation of the surveillance period. When patients can 
not be reached, certified letters that describe the malignant potential of molar 
pregnancy and the importance of follow-up should be sent to the last known 
address, or social workers could be enrolled to assist in locating the patient and 
ascertaining the reason for non-compliance. 
 
o The possibility of making the serum Beta-hCG surveillance tests free of charge, to 
take into account the socio-economic toll this protracted surveillance period takes.  
 
o Nursing and medical education programs which assist in the counseling of these 
patients, in an attempt to improve understanding of the disease and thus 
compliance. 
 
o The formulation of an information booklet that can be given to the newly diagnosed 
patient with all the relevant details on the surveillance procedure and the reason for 
its necessity. 
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o The forwarding of all patient details and the surveillance outcomes from peripheral 
hospitals to a centralized regional registry, namely the tertiary institution responsible 
for that drainage area. 
 
It seems more appropriate for these, as yet, uncomplicated patients to followed up at 
regional centres and local clinics where state-funded healthcare is offered until such time as 
persistence or recurrence is diagnosed, whereby they can appropriately be referred to a 
tertiary centre capable of managing the complication. All these cases could be recorded by 
the clinic and consultation with specialists would be available when necessary and all details 
are sent to the tertiary facility for registration in the molar registry. 
 
Conclusion 
The management of molar pregnancies at our institution and in our drainage area thus far 
has been exemplary. However with the recent data published and some confirmation from 
this study, improvement of patient compliance, education and primarily medical treatment 
and surveillance is necessary. The data in this study showing the potential for limiting the 
surveillance period must be viewed in context, based on the small sample size and the poor 
compliance to follow-up. The authors feel that a sensitivity of 0.89 and specificity of 0.88 is 
insufficient and feel it would be prudent to wait for more robust data before such changes 
are made. More research, in the form of a multi-centred prospective cohort study, is 
needed before the surveillance period can safely be shortened without impacting on 
maternal morbidity. The development of a central registry will be pivotal in allowing for the 
acquisition of the data required to make these changes.  
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Illustrations 
Table 1: Distinction between complete and partial moles 
Feature Complete mole Partial mole 
Karyotype Diploid: 46,XX (<15% 46,XY) Triploid: 69,XXX/Y, (rarely 
69,XYY) 
Embryonic/foetal tissue Typically absent (may be 
present in few cases) 
 
Present 
Villi Diffusely hydropic Hydropic villi with marked 
scalloping mixed with 
normal appearing chorionic 
villi and fetal tissue; 
hydropic changes are focal 
and less prominent than in 
complete mole 
Trophoblastic proliferation Hyperplastic Less trophoblastic 
hyperplasia than in 
complete mole; 
trophoblastic stromal 
inclusions can be seen 
Trophoblastic atypia Often present Infrequent 
Immunocytochemistry hCG, rare PLAP hCG, PLAP, p57 
Uterine size Often large for dates Often small for dates 
Theca lutein cysts Present in </= 25% Rare 
Malignant sequelae Occur in up to one-third Occur in less than 5 percent 
 




Age at Menarche 
Age at First Pregnancy 
Nicotine Use 
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Table 3: Comparison of PHM and CHM 
Variables Type of 
Molar 
Pregnancy 
Minimum Maximum Mean Standard 
deviation 
P-value 
Age CHM  13 23 26.0 9.5 0.633 
PHM 13 49 26.4 8.3 
Gravidity CHM 1 12 2.1 1.9 0.094 
PHM 1 7 2.4 1.6 
Parity CHM 0.0 11 0.9 1.8 0.099 
PHM 0.0 6 1.2 1.6 
Menarche CHM 11 16 13.62 1.310 0.404 
PHM 11 18 13.84 1.503 
Age at First 
Pregnancy 
CHM 13 42 20.58 4.49 0.445 
PHM 13 29 18.97 3.12 
TSH  CHM 0.010 113 3.6 17.1 0.116 
PHM 0.010 5.0 0.8 1.2 
Initial  
Beta-hCG 
CHM 1366 5407920 472715.6 817681 0.855 
PHM 2080 3467000 625496.2 900520.0 
 
Table 4: Comparison of Persistence compared to Age 
 Age < 35 years Age >/= 35 years P-value 
No Persistence 79 (83.2%) 17 (68%) 0.057 
Persistence 16 (16.8%) 8 (32%) 
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Table 5: Nonparametric comparisons of Descriptive variables between Persistent and Non-





Initial Beta-hCG 0.717 
 
 
Table 6: Beta-hCG Follow-up in patients with Complete and PHM’s 
Histology CHM PHM Unknown 
Persistence Present 13 (19.7%) 10 (20%) 1 (25%) 
No chemotherapy required, despite lack of 
remission diagnosis 
53 (80.3%) 40 (80%) 3 (75%) 
Lost to Follow-up < 6 months after evacuation 44 (66.6%) 25 (50%) 1 (25%) 
Did not follow up but had at least 1 undetectable 
Beta-hCG level 
14 (21%) 17 (34%) 3 (75%) 
Did not follow up and did not reach undetectable 
Beta-hCG levels 
49 (74.2%) 30 (60%) 2 (50%) 
Fell Pregnant during follow-up period, before 
remission 
3 (4.5%) 3 (6%) 0 
Missed at least 1 visit during first 6 months after 
evacuation 
57 (86.3%) 47 (94%) 4 (100%) 
Total (n=120) 66 (55%) 50 (42%) 4 (3%) 
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Table 7: Receiver Operator Characteristic Curves to Differentiate Beta-hCG levels 
 Number of 
Cases 
AUC Sensitivity Specificity Cut-off Beta-
hCG Value 
Week 1 77 0.76 0.69 0.79 6309 
Week 2 68 0.76 0.67 0.86 1813 
Week 3 69 0.78 0.92 0.67 174 
Week 4 83 0.85 0.94 0.73 148 
Week 6 85 0.9 0.89 0.88 148 
Month 2 86 0.84 0.82 0.87 43 
Month 3 76 0.72 0.64 0.8 11 
Month 4 72 0.71 0.67 0.7 2 
 
Table 8: Remission time intervals of molar pregnancies 
Remission diagnosis CHM PHM 
< 4 months 7 (30.4%) 9 (39.1%) 
4-6 months 13 (56.6%) 13 (56.6%) 
> 6 months 3 (13%) 1 (4.3%) 
Totals 23 23 
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Table 9: FIGO (2000) scoring system for gestational trophoblastic neoplasia, by prognostic 
factor 
 0 1 2 4 
Age < 40 > 40   
Antecedent 
Pregnancy 
Mole Abortion Term  
Interval to 
Chemotherapy 
< 4 months 4-6 months 7-12 months > 12 months 
Beta-hCG (IU/l) < 103 103 - < 104 104 - 105 > 105 
Number of 
Metastases 
0 1 - 4 5 - 8 > 8 
Site of 
Metastases 




 3 -5 CHM > 5 CHM  
Previous 
Chemotherapy 
  Monotherapy Combined 
Chemotherapy 
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LTFU < 6mo                    
44 (66%) 
>/= 1 
undetectable        




B-hCG                       
49 (74%) 
Spontaneous 
Remission           
23 (35%) 
Partial (n=50) 
LTFU < 6mo                    
25 (50%) 
> 1 
undetectable        




B-hCG                       
30 (60%) 
Spontaneous 





LTFU < 6mo                    
1 (25%) 
> 1 
undetectable        




B-hCG                       
2 (50%) 
Spontaneous 
Remission           
2 (50%) 
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Figure 2: Histogram of Maternal Age Distribution 
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Figure 4: Histogram of Gravidity Distribution 
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Figure 6: Histogram of Age at First Pregnancy Distribution 
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Figure 8: Box and Whisker Plot of Initial Beta-hCG Levels 
 
 
Figure 9: Histogram of Smoking Practices 
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Figure 10: Histogram of Treatment Modalities 
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Addendum A: Data Sheet 
  DATA SHEET  
Case Number       
Histology       
Age   Parity   Gravidity   
Nationality       
TSH:    Menarche  
T4:     First Pregnancy  
Beta-hCG:     Smoker (Y/N)   
Follow Up Beta-hCG      
Week 1       
Week 2       
Week 3       
Month 1       
Week 5       
Week 6       
Week 7       
Month 2       
Week 9       
Week 10       
Week 11       
Month 3       
Month 4       
Month 5       
Month 6       
Month 9       
Year 1       
Month 18       
Year 2       
Persistence (Y/N)       
Recurrence (Y/N)       
Lost to Follow-up (Y/N)       
Telephonically contacted 
(Y/N)       
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